bioRxivBiochemistry
Inhibition of CREB binding and function with a dual-targeting ligand
Y. Liu, S. T. Joy, M. J. Henley, J. A. Yates, S. D. Merajver, A. K. Mapp
Abstract
CBP/p300 is a master transcriptional coactivator, regulating gene activation by interacting with multiple transcriptional activators. Dysregulation of protein-protein interactions (PPIs) between the CBP/p300 KIX domain and its activators is implicated in a number of cancers including breast, leukemia, and colorectal cancer. However, KIX is typically considered undruggable because of its shallow binding surfaces lacking both significant topology and promiscuous binding profiles. We previously reported a dual-targeting peptide (MybLL-tide) that inhibits the KIX-Myb interaction with excellent specificity and potency. Here we demonstrate a branched, second-generation analog, CREBLL-tide, that inhibits the KIX-CREB PPI with higher potency and selectivity. Additionally, the best of these CREBLL-tide analogs shows excellent and selective anti-proliferation activity in breast cancer cells. These results indicate CREBLL-tide is an effective tool for assessing the role of KIX-activator interactions in breast cancer and expanding the dual-targeting strategy for inhibiting KIX and other coactivators that contain multiple binding surfaces.
- organism: human
- research focus: cancer & tumor microenvironment
- research focus: protein folding & dynamics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb
S. T. Joy, M. J. Henley, … A. Mapp·bioRxiv·Apr 28, 2021
- A lipopeptidomimetic of transcriptional activation domains selectively disrupts Med25 PPIs
O. N. Pattelli, E. Martinez Valdivia, … A. K. Mapp·bioRxiv·Mar 24, 2023
- CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells
A. Conery, A. Bommi-Reddy, … R. J. Sims·bioRxiv·Dec 26, 2021
- Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors
M. C. Crawford, D. R. Tripu, … J. L. Meier·bioRxiv·May 15, 2023
- MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity
Josefina Mendez, Simone Bruno, … Alex Toker·bioRxiv·Sep 22, 2026
- Undruggable oncoproteins cMyc and NMyc bind to mediator of transcription with superior high affinity
Andrea Knight, Josef Houser, … Martin Piskáček·Molecular MedicinePeer-reviewed·Nov 13, 2024